Business
Satipharm Gelpell Outperforms Sativex in Phase 1 Trial
Satipharm Gelpell Outperforms Sativex in Phase 1 Trial
About this update from Underwood Capital Limited
[{"type":"text","content":"Underwood Capital Limited has released a press release. View Attachment","length":244,"tagName":"div"}]